A total of 21 patients with bronchiectasis were enrolled and randomized into this, double-blind, placebo controlled Phase II study. The purpose of the trial is to investigate safety and efficacy of inhaled Alpha-1 Antitrypsin (AAT) in this patient population.
David Tsur, CEO of Kamada, said: “We are very pleased with the progress of this study and look forward to its upcoming completion. We believe that Kamada’s AAT delivered by Pari’s eFlow has the potential to become a novel treatment for bronchiectasis.
“Kamada is committed to the development of inhaled AAT to treat bronchiectasis and to proceed with its ongoing clinical efforts in AAT deficiency and cystic fibrosis.”